LARRY YET, Ph.D.

Department of Chemistry
University of South Alabama
6040 USA Drive South
Mobile, AL 36688

Phone: (251) 460-7434
E-mail: lyet@southalabama.edu

PROFESSIONAL EXPERIENCE

University of South Alabama, Department of Chemistry, Mobile, AL 36688
Associate Professor, August 2018–Present
Assistant Professor, August 2012–July 2018
Research Interests: Transition metal-catalyzed cross-coupling methodologies, C-H functionalization methodologies, natural products/SAR development of anticancer therapeutics, medicinal chemistry, drug discovery.

Albany Molecular Research, Inc. (AMRI), Albany, NY
Senior Research Scientist II, Medicinal Chemistry Department, April 2003–December 2006, July 2009–March 2011
Senior Research Scientist I, Medicinal Chemistry Department, April 2000–March 2003
Senior Research Scientist, Medicinal Chemistry Department, September 1996–March 2000

- Managed, supervised, coached, and mentored 2−5 scientists of all educational levels.
- Functioned as a project leader/lead scientist for multiple clients in short-term custom synthesis projects and long-term hit-to-lead/lead optimization programs in medicinal chemistry projects in cardiovascular, metabolic, anti-infectives, inflammatory diseases, oncology and CNS therapeutic areas.
- Communicated regularly with clients on current projects with teleconference, visits, and project updates.
- Audited and proposed new safety protocols for research laboratories.
- Actively recruited talented personnel for scientific and non-scientific positions.
- Prepared and analyzed client custom synthesis and research proposals.
- Participated in new therapeutic target proposals for the Research and Development Department for internal drug discovery programs.
- Consulted actively on projects with colleagues from satellite sites in India and Singapore.

Albany Molecular Research Singapore Research Centre, Pte. Ltd., Singapore
Team Leader, Discovery Services Department, January 2007–June 2009

- Part of the management team.
- Managed, supervised, coached, and mentored 15−25 scientists of all educational levels.
- Managed multiple clients and projects in custom synthesis, agricultural, material science and medicinal chemistry.
- Communicated regularly with clients on current projects with teleconferences, visits, and project updates.
- Safety Chairman of the entire site−presented, implemented, and evaluated current and

new safety protocols; liased with Singapore government for required licenses and regulatory compliances; attended four-day course on Safety Management of Waste.

- Actively recruited talented personnel for scientific and non-scientific positions in Singapore and India.
- Participated in Business Development roles−prepared/analyzed client custom synthesis and research proposals, presented AMRI business models to potential clients, and networked at symposiums for future business needs and opportunities.
- Outfitted new laboratory space with equipment, instruments and glassware.

EDUCATIONAL EXPERIENCE

Postdoctoral Research Fellow
The University of Delaware, Department of Chemistry and Biochemistry, Newark, DE, 1994–1996
Research Advisor: Professor Douglass F. Taber
Research Title: "Synthetic Studies Toward Taxol and Total Synthesis of α-Dictyopterol with Silicon-Based Methodologies"

M.S./Ph.D. Organic Chemistry
The Ohio State University, Department of Chemistry, Columbus, OH, 1987–1995
Research Advisor: Professor Harold Shechter
Dissertation Title: "1-(Benzenesulfonyl)-2-(trimethylsilyl)ethane Dianion as an Effective Synthetic Equivalent for Symmetrical 1,1-Disubstituted Terminal Olefins," and "Synthesis and Chemistry of 1-(Benzenesulfonyl)-2-(trimethylsilyl)cyclopropanes"
Thesis Title: "Study of 1-(Benzenesulfonyl)-4-(trimethylsilyl)-2-butenes: A Synthetic Equivalent for the 1-(1,3-Butadienyl) Anion"

B.Sc. Chemistry
The University of British Columbia, Department of Chemistry, Vancouver, British Columbia, Canada, 1983–1987
Research Advisor: Professor James P. Kutney
Senior Thesis: "The Partial Synthetic Route to Digitoxigenin"

PROFESSIONAL AFFILIATIONS

- Member of American Chemical Society
- Member of Medicinal Chemistry Division of the American Chemical Society
- Member of Organic Chemistry Division of the American Chemical Society
- Biography in Marquis Who's Who in the World, **2001**, 18th Edition.

- Reviewer for Angewandte Chemie International Edition, Canadian Journal of Chemistry, Chemistry-A European Journal, Journal of the American Chemical Society, Synthetic Communications, Tetrahedron, and Tetrahedron Letters journals, ACS Petroleum Grant Proposals, and Wiley Book Proposals.

PUBLICATIONS (undergraduate co-authors are underlined)

Research Papers:

1. Zhu, B., Lindsey, A., Li, N., Lee, K., Ramirez-Alcantara, V., Canzoneri, J. C., Fajardo, A., da Silva, L. M., Thomas, M., Piazza, J. T., Yet, L., Eberhardt, B. T., Gurpinar, E., Otali, D., Grizzle, W., Valiyaveettil, J., Chen, X., Keeton, A. B., Piazza, G. A., Yet, L. (2017). Phosphodiesterase 10A is overexpressed in lung tumor cells and inhibitors selectively suppress growth by blocking β-catenin and MAPK signaling. *Oncotarget, 8,* 69264–69280.

2. Chattopadhyay, D., Swingle, M. R., Salter, E. A., Wood, E., D'Arcy, B., Zivanov, C., Abney, K., Musiyenko, A., Rusin, S. F., Kettenbach, A. N., Yet, L., Schroeder, C. E., Golden, J. E., Dunham, W. H., Gingras, A.-C., Banerjee, S., Forbes, D., Wierzbicki, A., Honkanen, R. E. (2016). Crystal structures and mutagenesis of PPP-family ser/thr protein phosphatases elucidate the selectivity of cantharidin and novel norcantharidin-based inhibitors of PP5C. *Biochem. Pharmacol., 109,* 14–26.

3. Tuttle, M. R., Honkanen, R. E., Salter, E. A., Wierzbicki, A., Yet, L. (2016). Progress towards a norcantharidin-based scaffold for inhibition of the protein phosphatase 5C (PP5C) enzyme. *Proceedings of The National Conference on Undergraduate Research (NCUR), 30,* 471–475.

4. McElroy, W. T., Seganish, W. M., Herr, R. J., Harding, J., Yang, J., Yet, L., Komanduri, V., Prakash, K. C., Lavey, B., Tulshian, D., Greenlee, W. J., Sondey, C., Fischmann, T., Niu, X. (2015). Discovery and hit-to-lead optimization of 2,6-diaminopyrimidine inhibitors of interleukin receptor-associated kinase 4. *Bioorg. Med. Chem. Lett., 25,* 1836–1841.

5. Seganish, W. M., McElroy, W. T., Herr, R. J., Brumfield, S., Greenlee, W. J., Harding, J., Komanduri, V., Matasi, J., Prakash, K. C., Tulshian, D., Yang, J., Yet, L., Devito, K., Fossetta, J., Garlisi, C. G., Lundell, D., Niu, X., Sondey, C. (2015). Initial optimization and series evolution of diaminopyrimidine inhibitors of interleukin-1 receptor associated kinase 4. *Bioorg. Med. Chem. Lett., 25,* 3203–3207.

Research Papers:

6. Lee, K., Li, N., Xi, Y., Zhu, B., Gary, B. D., Ramirez-Alcantara, V., Gurpinar, E., Canzoneri, J. C., Fajardo, A., Sigler, S., Piazza, J. T., Chen, X., Andrews, J., Thomas, M., Lu, W., Li, Y., Laan, D. J., Moyer, M. P., Russo, S., Eberhardt, B. T., Yet, L., Keeton, A. B., Grizzle, W. E., Piazza, G. A. (2015). Phosphodiesterase 10A: a novel target for selective inhibition of colon tumor cell growth and β-catenin-dependent TCF transcriptional activity. *Oncogene, 34*, 1499–1509.

7. Liu, S., Zha, C., Nacro, K., Hu, M., Cui, W., Yang, Y.-L., Bhatt, U., Sambandam, A., Isherwood, M., Yet, L., Herr, M. T., Ebeltoft, S., Hassler, C., Fleming, L., Pechulis, A. D., Payen-Fornicola, A., Holman, N., Milanowski, D., Cotterill, I., Mozhaev, V., Khmelnitsky, Y., Guzzo, P. R., Sargent, B. J., Molino, B. F., Olson, R., King, D., Lelas, S., Li, Y.-W., Johnson, K., Molski, T., Orie, A., Ng, A., Haskell, R., Clarke, W., Bertekap, R., O'Connell, J., Lodge, N., Sinz, M., Adams, S., Zaczek, R., Macor, J. E. (2014). Design and synthesis of 4-heteroaryl 1,2,3,4-tetrahydroisoquinolines as triple reuptake inhibitors. *ACS Med. Chem. Lett., 5*, 760–765.

8. Collier, S. J., Wu, X., Poh, Z., Rajkumar, G. A., Yet, L. (2011). An alternative synthesis of bilastine. *Synth. Comm., 41*, 1394–1402.

9. He, S., Dobbelaar, P. H., Liu, J., Jian, T., Sebhat, I. K., Lin, L. S., Goodman, A., Guzzo, P. R., Hadden, M., Henderson, A. J., Sargent, B. J., Swenson, B., Yet, L., Kelly, T. M., Palyha, O., Kan, Y., Pan, J., Chen, H., Marsh, D. J., Shearman, L. P., Strack, A. M., Metzger, J. M., Feighner, S. D., Tan, C., Howard, A. D., Tamvakopoulos, C., Peng, Q., Guan, X.-M., Reitman, M. L., Patchett, A. A., Wyvratt, M. J., Nargund, R. P. (2010). Discovery of substituted biphenyl imidazoles as potent, bioavailable bombesin receptor subtype-3 agonists. *Bioorg. Med. Chem. Lett., 20,* 1913–1917.

10. Liu, J., He, S., Jian, T., Dobbelaar, P. H., Sebhat, I. K., Lin, L. S., Goodman, A., Guo, C., Guzzo, P. R., Hadden, M., Henderson, A. J., Pattamana, K., Ruenz, M., Sargent, B. J., Swenson, B., Yet, L., Tamvakopoulos, C., Peng, Q., Pan, J., Kan, Y., Palyha, O., Kelly, T. M., Guan, X.-M., Howard, A. D., Marsh, D. J., Metzger, J. M., Reitman, M. L., Wyvratt, M. J., Nargund, R. P. (2010). Discovery of substituted biphenyl imidazoles as potent, bioavailable bombesin receptor subtype-3 agonists. *Bioorg. Med. Chem. Lett., 20*, 2074–2077.

11. Arvapalli, V. S., Chen, G., Kosarev, S., Tan, M. E., Xie, D., Yet, L. (2010). Microwave-assisted organic synthesis of 3-substituted-imidazo[1,5-*a*]pyridines. *Tetrahedron Lett., 51*, 284–286.

Research Papers:

13. Hadden, M., Goodman, A., Guo, C., Guzzo, P. R., Henderson, A. J., Pattamana, K., Ruenz, M., Sargent, B. J., Swenson, B., Yet, L., Liu, J., He, S., Sebhat, I. K., Lin, L. S., Tamvakopoulos, C., Peng, Q., Kan, Y., Palyha, O., Kelly, T. M., Guan, X.-M., Metzger, J. M., Reitman, M. L., Nargund, R. P. (2010). Synthesis and SAR of heterocyclic carboxylic acid isoteres based on 2-biarylethylimidazole as bombesin receptor subtype-3 (BRS-3) agonists for the treatment of obesity. *Bioorg. Med. Chem. Lett., 20*, 2912–2915.

14. Guo, C., Guzzo, P. R., Hadden, M., Sargent, B. J., Yet, L., Kan, Y., Palyha, O., Kelly, T. M., Guan, X., Rosko, K., Gagen, K., Metzger, J. M., Dragovic, J., LyonS, K., Lin, L. S., Nargund, R. P. (2010). Synthesis of 7-benzyl-5-(piperidin-1-yl)-6,7,8,9-tetrahydro-3*H*-pyrazolo[3,4-c]-[2,7]naphthyridin-1-ylamine and its analogs as bombesin receptor subtype-3 agonists. *Bioorg. Med. Chem. Lett., 20*, 2785–2789.

15. Campbell, R. F., Fitzpatrick, K., Reilly, J. E., Yet, L., Inghardt, T., Karlsson, O. (2003). Enzymatic resolution of substituted mandelic acids. *Tetrahedron Lett., 44*, 5477–5481.

16. Meagher, T., Yet, L., Hsaio, C.-H., Shechter, H. (1998). (E)- and (Z)-1-(Phenylsulfonyl)-4-(trimethylsilyl)-2-butenes: synthetic equivalents for the 1-(1,3-butadienyl) anion and the 1,1-(1,3-Butadienyl) Dianion. *J. Org. Chem., 63*, 4181–4192.

17. Taber, D. F., Yet, L., Bhamidipati, R. S. (1995). Conversion of phenyldimethylsilyl to the hydroxyl in the presence of a carbon-carbon double bond. *Tetrahedron Lett., 36*, 351–354.

18. Taber, D. F., Bhamidipati, R. S., Yet, L. (1995). Phenyldimethylsilyl as an alcohol surrogate in intramolecular Diels-Alder cycloaddition: synthesis of α-dictyopterol. *J. Org. Chem., 60*, 5537–5539.

Journal Review Articles: (undergraduate co-authors are underlined)

1. Yet, L., Mullen, G. E. (2015). Recent Progress in the Development of Fatty Acid Synthase Inhibitors as Anticancer Target. *Bioorg. Med. Chem. Lett., 25*, 4363–4369.

2. Yet, L. (2003). The Chemistry and Biology of Salicylihalamide A and Related Compounds. *Chem. Rev., 103*, 4283–4306.

3. Yet, L. (2001). Recent Developments in Catalytic Asymmetric Strecker-Type Reactions. *Agnew. Chemie Int. Ed., 40*, 875–877.

4. Yet, L. (2000). Metal-Mediated Synthesis of Medium-Sized Rings. *Chem. Rev., 100*, 2963–3008.

5. Yet, L. (1999). Free Radicals in the Synthesis of Medium-Sized Rings. *Tetrahedron, 55*, 9349–9403.

Books

1. Yet, L. (2018). *Privileged Structures in Drug Discovery: Medicinal Chemistry and Synthesis*. pp. 1–560, New York: John Wiley & Sons, Inc.

2. Yet, L. (2016). The Olefin Ring-Closing Metathesis Reaction. *Organic Reactions* (vol. 89, pp. 1–1303). New York: John Wiley & Sons.

Book Chapters:

1. Yet, L. (2018). Five-Membered Ring Systems: With More than One N Atom. In G. W. Gribble & J. Joule (Eds.), *Progress in Heterocyclic Chemistry* (vol. 30, In Press). Oxford: Pergamon.

2. Yet, L. (2018). Six-Membered Ring Systems: Pyridine and Benzo Derivatives. In G. W. Gribble & J. Joule (Eds.), *Progress in Heterocyclic Chemistry* (vol. 30, In Press). Oxford: Pergamon.

3. Yet, L. (2017). Five-Membered Ring Systems: With More than One N Atom. In G. W. Gribble & J. Joule (Eds.), *Progress in Heterocyclic Chemistry* (vol. 29, pp. 279–315). Oxford: Pergamon.

4. Yet, L. (2016). Five-Membered Ring Systems: With More than One N Atom. In G. W. Gribble & J. Joule (Eds.), *Progress in Heterocyclic Chemistry* (vol. 28, pp. 275–315). Oxford: Pergamon.

5. Yet, L. (2015). Five-Membered Ring Systems: With More than One N Atom. In G. W. Gribble & J. Joule (Eds.), *Progress in Heterocyclic Chemistry* (vol. 27, pp. 247–285). Oxford: Pergamon.

6. Yet, L. (2014). Five-Membered Ring Systems: With More than One N Atom. In G. W. Gribble & J. Joule (Eds.), *Progress in Heterocyclic Chemistry* (vol. 26, pp. 237–277). Oxford: Pergamon.

7. Yet, L. (2013). Five-Membered Ring Systems: With More than One N Atom. In G. W. Gribble & J. Joule (Eds.), *Progress in Heterocyclic Chemistry* (vol. 25, pp. 217–256). Oxford: Pergamon.

Book Chapters:

8. Yet, L. (2012). Five-Membered Ring Systems: With More than One N Atom. In G. W. Gribble & J. Joule (Eds.), *Progress in Heterocyclic Chemistry* (vol. 24, pp. 243–279). Oxford: Pergamon.

9. Yet, L. (2012). Six-Membered Ring Systems: Diazenes and Benzo Derivatives. In G. W. Gribble & J. Joule (Eds.), *Progress in Heterocyclic Chemistry* (vol. 24, pp. 393–420). Oxford: Pergamon.

10. Yet, L. (2011). Five-Membered Heterocycles with Three Heteroatoms: Triazoles. In J. Barluenga & J. Alvarez-Builla (Eds.), *Modern Heterocyclic Chemistry* (vol. 2, pp. 989–1045). Weinheim: Wiley-VCH.

11. Yet, L. (2011). Five-Membered Ring Systems: With More than One N Atom. In G. W. Gribble & J. Joule (Eds.), *Progress in Heterocyclic Chemistry* (vol. 23, pp. 231–266). Oxford: Pergamon.

12. Yet, L. (2011). Five-Membered Ring Systems: With More than One N Atom. In G. W. Gribble & J. Joule (Eds.), *Progress in Heterocyclic Chemistry* (vol. 22, pp. 217–257). Oxford: Pergamon.

13. Yet, L. (2009). Five-Membered Ring Systems: With More than One N Atom. In G. W. Gribble & J. Joule (Eds.), *Progress in Heterocyclic Chemistry* (vol. 20, pp. 190–219). Oxford: Pergamon.

14. Yet, L. (2009). Five-Membered Ring Systems: With More than One N Atom. In G. W. Gribble & J. Joule (Eds.), *Progress in Heterocyclic Chemistry* (vol. 21, pp. 224–260). Oxford: Pergamon.

15. Yet, L. (2009). Hiyama Cross-Coupling Reaction. In J. J. Li (Ed.), *Name Reactions for Homologation Part 1* (vol. 1, pp. 33–46). Hoboken: John Wiley & Sons, Inc..

16. Yet, L. (2009). Nozaki-Hiyama-Kishi Reaction. In J. J. Li (Ed.), *Name Reactions for Homologation Part 1* (vol. 1, pp. 299–318). Hoboken: John Wiley & Sons, Inc..

17. Yet, L. (2009). The Negishi-Cross-Coupling Reaction. In J. J. Li (Ed.), *Name Reactions for Homologation Part 1* (vol. 1, pp. 70–99). Hoboken: John Wiley & Sons, Inc..

18. Yet, L. (2008). Five-Membered Ring Systems: With More than One N Atom. In G. W. Gribble & J. Joule (Eds.), *Progress in Heterocyclic Chemistry* (vol. 19, pp. 208–241). Oxford: Pergamon.

Book Chapters:

19. Yet, L. (2008). Pyrazoles. In A. R. Katritzky, C. A. Ramsden, E. F.V. Scriven, & R. J.K. Taylor (Eds.), *Comprehensive Heterocyclic Chemistry III* (vol. 4, pp. 1–141). Oxford: Elsevier Ltd..

20. Yet, L., Johnson, D. S. (2007). Angiotensin AT1 Antagonists for Hypertension. In J. J. Li (Ed.), *Art of Drug Synthesis* (pp. 129–141). Hoboken: John Wiley & Sons, Inc..

21. Yet, L. (2007). Five-Membered Ring Systems: With More than One N Atom. In G. W. Gribble & J. Joule (Eds.), *Progress in Heterocyclic Chemistry* (vol. 18, pp. 218–246). Oxford: Pergamon.

22. Yet, L. (2005). Five-Membered Ring Systems: With More than One N Atom. In G. W. Gribble & J. Joule (Eds.), *Progress in Heterocyclic Chemistry* (vol. 17, pp. 172–196). Oxford: Pergamon.

23. Yet, L. (2004). Five-Membered Ring Systems: With More than One N Atom. In G. W. Gribble & J. Joule (Eds.), *Progress in Heterocyclic Chemistry* (vol. 16, pp. 198–227). Oxford: Pergamon.

24. Yet, L. (2003). Five-Membered Ring Systems: With More than One N Atom. In G. W. Gribble & J. Joule (Eds.), *Progress in Heterocyclic Chemistry* (vol. 15, pp. 206–229). Oxford: Pergamon.

25. Yet, L. (2003). Recent Developments in Catalytic Asymmetric Strecker-Type Reactions. In H.-G. Schmalz & T. Wirth (Eds.), *Organic Synthesis Highlights V* (pp. 187–193). Weinheim: Wiley-VCH.

26. Yet, L. (2002). Five-Membered Ring Systems: With More than One N Atom. In G. W. Gribble & J. Joule (Eds.), *Progress in Heterocyclic Chemistry* (vol. 14, pp. 180–199). Oxford: Pergamon.

27. Yet, L. (2001). Five-Membered Ring Systems: With More than One N Atom. In G. W. Gribble & J. Joule (Eds.), *Progress in Heterocyclic Chemistry* (vol. 13, pp. 167–187). Oxford: Pergamon.

28. Yet, L. (2000). Five-Membered Ring Systems: With More than One N Atom. In G. W. Gribble & J. Joule (Eds.), *Progress in Heterocyclic Chemistry* (vol. 12, pp. 161–184). Oxford: Pergamon.

Patents:

1. Seganish, W. M., McElroy, W. T., Brumfield, S., Herr, R. J., Yet, L., Yang, J., Harding III, J. P., Ho, G. D., Tulshian, D., Yu, W., Wong, M. K.C., Lavey, B., Kozlowski, J. A. (2017). *Inhibitors of IRAK4 Activity*. US 9,598,440 B2.

2. Guzzo, P. R., Molino, B. F., Cui, W., Liu, S. J., Olson, R. E., Yet, L. (2015). *Aryl- and Heteroaryl-substituted Tetrahydrobenzo-1,4-diazepines and Use Thereof to Block Reuptake of Norepinephrine, Dopamine, and Serotonin*. US 9,096,546 B2.

3. Seganish, W. M., McElroy, W. T., Brumfield, S., Herr, R. J., Yet, L., Yang, J., Harding, III, J. P., Ho, G. D., Tulshian, D., Yu, W., Wong, M. K.C., Lavey, B., Kozlowski, J. A. (2014). *Inhibitors of IRAK4 Activity*. WO 2014/058685 A1.

4. Dobbelaar, P. H., Franklin, C. L., Goodman, A., Guo, C., Guzzo, P. R., Hadden, M., He, S., Henderson, A. J., Jian, T., Lin, L. S., Liu, J., Nargund, R. P. N, Ruenz, M., Sargent, B. J., Sebhat, I. K., Yet, L. (2012). *Substituted Imidazoles as Bombesin Receptor Subtype-3 Modulators*. US 8,183,275 B2.

5. Dobbelaar, P. H., Franklin, C. L., Goodman, A., Guo, C., Guzzo, P. R., Hadden, M., He, S., Henderson, A. J., Jian, T., Lin, L. S., Liu, J., Nargund, R. P. N, Ruenz, M., Sargent, B. J., Sebhat, I. K., Yet, L. (2008). *Substituted Imidazoles as Bombesin Receptor Subtype-3 Modulators*. WO 2008/051405 A1.